What is Niowave?
Niowave operates at the intersection of advanced physics and clinical medicine, serving as a premier supplier of medical radioisotopes. The company utilizes proprietary accelerator technology and sophisticated radiochemistry to manufacture Actinium-225 (Ac-225), a vital component in the development of next-generation targeted cancer therapies. By addressing systemic bottlenecks in the medical isotope supply chain, Niowave provides the necessary reliability and scalability required by healthcare providers and research institutions to advance life-saving cancer treatments from clinical development to commercialization.
How much funding has Niowave raised?
Niowave has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in Niowave
PPP
Public-Private Partnership
What's next for Niowave?
With this late-stage funding, Niowave is poised to scale its manufacturing capabilities to meet the surging demand for targeted radiopharmaceuticals. The strategic focus will likely shift toward expanding production facilities and optimizing the distribution of critical isotopes to support global clinical trials. As the oncology landscape increasingly pivots toward precision medicine, Niowave's ability to maintain a consistent, high-purity supply of radioisotopes will be a key determinant in its long-term market dominance and its ability to facilitate broader access to innovative cancer care.
See full Niowave company page
